Bionano Genomics
BNGO
143 hedge funds and large institutions have $114M invested in Bionano Genomics in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 42 reducing their positions, and 18 closing their positions.
77% more call options, than puts
Call options by funds: $2.82M | Put options by funds: $1.59M
0.01% more ownership
Funds ownership: 0.04% → 0.05% (+0.01%)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
3% less funds holding
Funds holding: 148 → 143 (-5)
12% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 42
39% less capital invested
Capital invested by funds: $187M → $114M (-$73.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$6.09M |
| 2 |
BlackRock
New York
|
+$4.16M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.12M |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$2.07M |
| 5 |
Morgan Stanley
New York
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.07M |
| 2 |
D.E. Shaw & Co
New York
|
-$701K |
| 3 |
Jane Street
New York
|
-$658K |
| 4 |
Millennium Management
New York
|
-$620K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$415K |
BNGO Hedge Fund Activity: Q2 2022 in Review
143 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q2 2022, worth a combined $114M — down 39% from $187M a quarter earlier.
Fund positioning in BNGO was balanced in Q2 2022: 18 funds opened new positions, 18 closed out, 37 added to existing stakes and 42 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $6.09M. The largest seller was Principal Financial Group, cutting an estimated $1.07M.
- 143 institutional investors held Bionano Genomics (BNGO) as of Q2 2022, down from 148 in Q1 2022.
- Funds reported $114M of Bionano Genomics stock for Q2 2022, down 39% quarter-over-quarter.
- 18 funds opened new Bionano Genomics positions in Q2 2022 and 18 closed out, a net change of 0 holders.
- The largest Bionano Genomics buyer in Q2 2022 was Renaissance Technologies, an estimated $6.09M added.
- The largest Bionano Genomics seller in Q2 2022 was Principal Financial Group, an estimated $1.07M sold.
Based on aggregated 13F filings for Q2 2022.